Treatment of Type 2 Diabetes: One Size Does Not Fit All
|
|
- Marion Randall
- 8 years ago
- Views:
Transcription
1
2 Treatment of Type 2 Diabetes: One Size Does Not Fit All Lisa Kroon, PharmD, CDE, FCSHP Professor and Chair, Clinical Pharmacy School of Pharmacy, University of California San Francisco
3 Disclosure No conflict of interest to disclose
4 Learning Objectives 1. Summarize the key changes to the ADA Standards of Medical Care in Diabetes Review the classes of medications used in type 2 diabetes and their place in therapy. 3. Discuss the ADA approaches to glycemic treatment for type 2 diabetes with emphasis on how to individualize therapy, taking into account evidence of particular therapies on their effect on reducing the risk of long-term diabetes complications.
5 Case Study MK, a 52 year old male, was diagnosed with type 2 diabetes by his primary care provider. [A1C 8.1%; LDL-C 66;TG 148;HDL-C 53; BMI 32; BP136/80]. Other medical problems include hypertension (on HCTZ 25 mg daily, benazepril 40 mg daily) and dyslipidemia (on atorvastatin 40 mg daily). He was started on metformin by his PCP. Over the next 2 months, the metformin is titrated to 1000 mg BID. His A1C is now 7.1%. What is your assessment of his glycemic control? Is he at goal? What are other strategies for his glycemic control and overall diabetes management? What other standards of care for diabetes should MK receive?
6 Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 [12-14% in 2012] ~1-1.5 Million Type 1 (5%) Diabetes (A1C 6.5%) 29.1 Million (9.3%) 2/3 Diagnosed ~28 Million Type 2 1/3 Undiagnosed (8.1 Million) Pre-Diabetes (A1C %) 86 Million (37%; people age 20 and older) 50% of U.S. population has either prediabetes or diabetes
7 Age-Adjusted Prevalence of Obesity and Diagnosed Diabetes Among U.S. Adults Aged 18 Years or older Obesity (BMI 30 kg/m 2 ) No Data <14.0% % % % >26.0% Diabetes No Data <4.5% % % % >9.0% CDC s Division of Diabetes Translation. National Diabetes Surveillance System available at
8 UKPDS 10-year Cohort Data: Reductions with Intensive Vs. Conventional Therapy A1C results: 7.0% vs 7.9% 0 HbA 1c All-Cause Mortality Diabetes-Related Death Any Diabetes- Related Complication Myocardial Infarction Microvascular Complication % -6% -10% -12% (p=0.029) For every 1 % A1C, a 35% in risk of microvascular complications -16% (p=0.052) -25% (p=0.0099) UKPDS Group. Lancet. 1998;352:
9 UKPDS-10 year Follow-Up Glucose Control Holman RR et al. NEJM 2008;359:1577 [UKPDS 80] 3,277 patients (of 4,209) entered post-trial monitoring; seen annually for 5 years Mean Glycated Hemoglobin: Difference between conventional and control groups lost within 1 year after study ended
10 Outcome UKPDS-10 year Follow-Up Clinical Outcomes SFU and Insulin Groups Relative Risk (p-value) Metformin Group Relative Risk (pvalue) Any DM-related endpoint 9% (0.04) 21% (0.01) MI 15% (0.01) 33% (0.005) Microvascular disease 24% (0.001) 16% (0.31) Death from any cause 13% (0.007) 27% (0.002) Legacy Effect Holman RR et al. NEJM 2008;359:1577 [UKPDS 80]
11 Impact of Intensive Therapy for Diabetes: Summary of Major Clinical Trials Study Microvasc CVD Mortality UKPDS DCCT / EDIC* ACCORD ADVANCE VADT Kendall DM, Bergenstal RM. International Diabetes Center 2009 UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854. Holman RR et al. N Engl J Med. 2008;359:1577. DCCT Research Group. N Engl J Med 1993;329;977. Nathan DM et al. N Engl J Med. 2005;353:2643. Gerstein HC et al. N Engl J Med. 2008;358:2545. Patel A et al. N Engl J Med 2008;358:2560. Duckworth W et al. N Engl J Med 2009;360:129. (erratum: Moritz T. N Engl J Med 2009;361:1024) Initial Trial Long Term Follow-up * in T1DM
12 STANDARDS OF MEDICAL CARE IN DIABETES 2015
13 Antihyperglycemic Therapy in Type 2 Diabetes ADA. 7. Approaches to Glycemic Treatment. Diabetes Care 2015;38(suppl 1):S43. Figure 7.1; adapted with ADA. Standards of Medical Care permission Diabetes from Inzucchi Care SE, et 2015;38;Suppl al. Diabetes Care, 2015;38:
14 Glycemic Goals HbA1c < 7.0% (mean PG mg/dl) Pre-prandial PG mg/dl Post-prandial PG <180 mg/dl Individualization is key: Tighter targets (<6.5%) - younger, healthier Looser targets (<8.0%) - older, comorbidities, hypoglycemia prone, etc. Avoidance of hypoglycemia PG=plasma glucose Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print]
15
16 Approach to the Management of Hyperglycemia ADA. 6. Glycemic Targets. Diabetes Care 2015;38(suppl 1):S37. Figure 6.1; adapted with permission from Inzucchi SE, et al. Diabetes Care, 2015;38:
17 Lifestyle Modification Therapeutic options: Lifestyle - Weight optimization - Healthy diet ( nutrition therapy ) - Increased activity level Diabetes Care, Diabetologia. 19 April 2012 [Epub ahead of print]
18 20 oz bottle 65 gm CHO (sugar) 75 mg sodium 240 calories
19 Why Metformin as 1 st Line? Only type 2 DM medication shown to have long-term impact on macrovasular complications Stimulates AMP-activated protein kinase, which hepatic glucose output Inhibits mitochondrial respiratory chain, causing shift towards anaerobic metabolism (lactate is by-product) resulting in energy for gluconeogenesis +CV effects: TG, LDL-C, HDL-C; improves endothelial function Other effects:? anticancer properties SE: GI (diarrhea, nausea, anorexia, metallic taste), lactic acidosis, vit B 12 deficiency No weight gain; no hypoglycemia (except when used in combo therapy) Inzucchi SE. JAMA, 2014;314: Salpeter SR. Arch Intern Med. 2003;163:2550.
20 Metformin: CI/Precautions Jan 2009 Glucophage package insert Contraindications Renal disease or dysfunction scr 1.4 mg/dl in women and 1.5 mg/dl in men abnormal creatinine clearance; particularly cautious if 80 yrs of age Acute or chronic metabolic acidosis Precautions Active liver disease Excessive alcohol use or alcoholism Hypoxic states (HF-unstable/acute; acute MI) Other: radiologic studies using iodinated contrast materials (stop at time of/prior to and withhold 48 hr after)
21 Metformin in Renal Dysfunction Incidence of lactic acidosis among metformin users is 3 to 10/100,000 person-years (almost indistinguishable from rate in people with diabetes not on metformin) Suggested approach: Inzucchi SE. JAMA, 2014;314:
22 Case Study MK, a 52 year old male, was diagnosed with type 2 diabetes by his primary care provider. [A1C 8.1%; LDL-C 66;TG 148;HDL-C 53; BMI 32; BP136/80]. Other medical problems include hypertension (on HCTZ 25 mg daily, benazepril 40 mg daily) and dyslipidemia (on atorvastatin 40 mg daily). He was started on metformin by his PCP. Over the next 2 months, the metformin is titrated to 1000 mg BID. His A1C is now 7.1%. What is your assessment of his glycemic control? Is he at goal? Yes, or close to What are other strategies for his glycemic control and overall diabetes management? Diet, physical activity, SMBG if not already What other standards of care for diabetes should MK receive? Immunizations (PCV13, PPSV23), albuminuria test, ophtho (annual; or q2-3 years if no retinopathy present), other CV risk reduction (BP, lipids)
23 Case Study, cont d It is now 2 years later and MK still is taking metformin 1000 mg po BID. Labs: A1C 8.3% (was as low as 6.5% 1 year after starting metformin); Cr 0.9;LFT s wnl; BMI 28. What is your assessment? What is his A1C goal? What do you recommend?
24 Advancing to Dual Therapy On meformin already: SFU (or glinide) DPP-4 inhibitor GLP-1 RA TZD SGLT-2 inhibitor Insulin (usually basal insulin)
25 Antihyperglycemic Therapy in Type 2 Diabetes Combination Therapy: Combine Agents with Different Mechanisms of Action ADA. 7. Approaches to Glycemic Treatment. Diabetes Care 2015;38(suppl 1):S43. Figure 7.1; adapted with permission from Inzucchi SE, et al. Diabetes Care, 2015;38:
26 DPP-4 Inhibitors GLP-1 Rec. Agonists SFUs/Glinides GLP-1 Rec. Agonists Acarbose Miglitol TZDs Metformin
27 TZDs & CVD Risk: Rosiglitazone On 9/22/2010, rosiglitazone become available through restricted access only (meta-analysis in NEJM, 5/21/07 and redone in significantly risk of MI by 28% [OR 1.28]) June 5-6, 2013, readjudicated results of RECORD were discussed by FDA; committee members voted to eliminate REMS or lessen restrictions. FDA announced (11/25/13) to remove restrictions on Avandia.
28 Pioglitazone & CVD risk and other ADEs Pioglitazone does not appear to have MI risk, however does increase risk for heart failure Observational study suggests rosi has HR for heart failure of 1.25 compared to pioglitazone in an elderly population (Graham DJ et al. JAMA 2010;304) On 8/4/11, FDA updated safety announcement indicated label changes to Actos to reflect that use of pioglitazone for more than one year may be associated with an increased risk of bladder cancer. TZDs use due to ADEs (e.g., increases risk HR, edema, reduced bone density) have reduced use overall
29 Incretin-Based Therapies Gut hormones released postprandially 2 main gut incretins Glucose-dependent insulinotropic polypeptide (GIP) Released by K cells in duodenum Glucagon-like peptide-1 (GLP-1) Released by L cells in small intestines Levels are diminished in type 2 DM post-meal; t 1/2 <2 minutes Rapidly degraded by dipeptidyl peptidase IV (DPP-IV) GLP-1 analogs (injectable) Exenatide (BID and weekly) Liraglutide (injected daily) Albiglutide (injected weekly) Dulaglutide (injected weekly) DPP-IV inhibitors (oral, daily): sitagliptin, saxagliptin, linagliptin, alogliptin
30 Incretin Effect in Healthy Subjects Oral Glucose Intravenous (IV) Glucose Incretin effect accounts for 50-70% of insulin response to oral glucose. Vilsboll T et al. Diabetologia. 2004;47: Plasma Glucose (mg/dl) C-peptide (nmol/l) 2.0 * 1.5 * * * Incretin Effect * * * Time (min) N = 6; Mean (SE); *P 0.05 Data from Nauck MA, et al. J Clin Endocrinol Metab. 1986;63: Time (min)
31 Actions of GLP-1 GLP-1: Secreted upon the ingestion of food Promotes satiety and inhibits appetite Alpha cells: Postprandial glucagon secretion Beta cells: -Enhances glucose-dependent insulin secretion - Beta cell mass - apoptosis Liver: Glucagon reduces hepatic glucose output Stomach: Slows gastric emptying Data from Flint A, et al. J Clin Invest. 1998;101: ; Data from Larsson H, et al. Acta Physiol Scand. 1997;160: Data from Nauck MA, et al. Diabetologia. 1996;39: ; Data from Drucker DJ. Diabetes. 1998;47:
32 2-h Postprandial Plasma GLP-1 (pm) Postprandial Plasma Levels of Exenatide Exceeded Physiologic Levels of GLP h Plasma Exenatide (pm) Baseline Exenatide Sitagliptin Plasma GLP-1 Plasma Exenatide Patients with T2D; Evaluable population, n = 61 for all treatment groups; Mean ± SE 2-wk post-treatment concentration data; DeFronzo RA, et al. Curr Med Res Opin 2008; 24:
33 GLP-1 Agonists: Nausea While nausea declines after 3 weeks, it persists in some patients. Pratley R et al. Int J Clin Pract 2011;65:
34 Comparison of GLP-1 RAs (A1C) DeVries JH et al. Diabetes Care. 2012
35 Comparison of GLP-1 RAs (A1C) DeVries JH et al. Diabetes Care. 2012
36 Liraglutide shows improved effect on weight compared to other therapies Niswender K et al. Diabetes Obes Metab. 2013
37 GLP-1 RAs + Insulin (basal) Balena R et al. Diabetes Obes Metab. 2012
38 Sequential intensification of therapy with liraglutide followed by basal insulin DeVries JH et al. Diabetes Care. 2012
39 GLP-1 RA can help counteract weight gain with insulin DeVries JH et al. Diabetes Care. 2012
40 GLP-RAs vs. DPP-4 Inhibitors (not head-to-head) Aroda VR et al. Clinical Therapeutics. 2012
41 DPP4-Inhibitors: head-to-head with other oral agents AJ Scheen. Diabetes & Metabolism. 2012
42 Incretin Agents: Safety Concerns Thyroid cancer and neoplasia Thyroid C-cell tumors in rodent models CI/not recommended for use in patients with personal or family history of MTC (medullary thyroid cancer) or MEN 2 Joint pain (08/28/15: FDA safety alert for DPP-4 inhibitors) Pancreatic cancer Butler et al. Diabetes 2013 Exocrine cell proliferation and dysplasia (panins) Pancreatitis
43 Incretin Therapy and Pancreatitis Pancreatitis 1 st noted with exenatide ( cases per 1000 patient years) Risk of pancreatitis difficult to determine due to: Low event rate Type 2 diabetes associated with 3-fold increased risk FDA and EMA independent reviews of patient and animal data: no evidence of causal relationship, but recommend risk to be disclosed and further investigation (Egan et al, NEJM 2014) Avoid if history of pancreatitis, gallstones, alcoholism, hypertriglyceridemia Patient education: abdominal pain (persistent, severe, radiating to back, N/V, anorexia) to contact provider
44 Lack of increased risk of pancreatitis specific to incretin-based therapy use Thomsen RW et al. Diabetes Care. 2015
45 SGLT-2 inhibitors SGLT-2 inhibitor class: inhibit sodium glucose cotransporter-2 in proximal tubules, where ~90% of glucose filtered through nephron is reabsorbed Chao EC & Henry RR. Nat Rev Drug Disc. 2010
46 SGLT-2 Inhibitors, cont. Several options 3/29/13: canagliflozin (Ivokana): FDA safety alert for bone fracture risk/decreased bone density 1/8/14: dapagliflozin (Farxiga): Previously rejected approval 1/2012 due to breast & bladder cancer concerns; Do no use in patients with bladder cancer 08/01/14: empagliflozin (Jardiance) ADEs Common side effects: genital fungal infections and UTIs (due to increased glucose in urine) Increased risk of dehydration, hypovolemia, hypotension, dizziness in 1 st few months (diuretic effect) egfr limits (<45, 60 GFR) Euglycemic DKA reports A1C lowering
47 Ongoing CV Risk Outcome Trials Drug Trial Name ClinicalTrials.gov identifier Dulaglutide REWIND NCT Exenatide EXSCEL NCT Liraglutide LEADER NCT Canagliflozin CANVAS NCT Dapagliflozin DECLARE-TIMI58 NCT Empagliflozin EMPA-REG OUTCOME* NCT Multiple oral agents BMS NCT TZDs vs. SFUs TOSCA-IT NCT Linagliptin vs. Glimepiride CAROLINA NCT Completed Insulin glargine (U-100) ORIGIN NCT Saxagliptin SAVOR-TIMI53 NCT Sitagliptin TECOS NCT *Promising data at EASD 2015
48 Saxagliptin & CV Outcomes Note: rate of hospitalization for HF increased Scirica BM et al. NEJM. 2013
49 Sitagliptin and CV Outcomes Green JB et al. NEJM. 2015
50 Case Study, cont d What 2 nd agent would you add? SFU ( or glinide) DPP-4 inhibitor GLP-1 RA SGLT-2 inhibitor Insulin
51 Advancing to Triple Therapy? Which One? (added to metformin & SFU) Gross JL. Ann Intern Med. 2011;154:672-79
52 Case Study, cont d How would you modify his therapy if he was obese? he developed renal dysfunction? he had severe liver dysfunction? this was a postmenopausal woman (or person with osteopenia/osteoporosis)? he was elderly with a history of an MI? his A1C was 10.4% on metformin only? Or on 2 (or 3) non-insulin therapies?
53 Individualizing Therapy: Examples Circumstance Avoid Consider Renal dysfunction Metformin, certain SFUs Glipizide, glinides, DPP-4 inhibitors (dose adjust) Severe liver dysfunction Most agents Insulin, metformin Overweight/obese TZD Metformin, GLP-1 agonist, DPP- 4 inhibitor Heart failure Reduced bone density or osteoporosis History of pancreatitis History of bladder cancer TZD, metformin (only unstable/severe) TZD, Canagliflozin GLP-1 agonist, DPP-4 inhibitor Pioglitazone, Dapagliflozin Most other agents Most other agents Most other agents Most other agents Pre-existing edema TZD Most other agents Joint pain DPP-4 inhbitors Most other agents
54 1. Set A1C target Patient factors Individualizing Care Provider considerations 2. Assess how close patient is to target Why or why not? Changes since last visit (improve/worsen/same) Assess adherence, medication SEs, lifestyle (exercise, meals); psychosocial factors 3. Create a patient-specific plan to reach target Is patient on submax/therapeutic dose of particular medication? Titrate Is patient on max/therapeutic dose of medication? Add-on? Insulin? Adapted from Anne Peters, MD. February 9, 2014
55 Individualizing Care, cont d 4. Goal setting
56 Individualizing Care, cont d 5. Summarize plans from visit Teach back Handouts 6. Follow-up Continual guidance/support n/smeactionplan
57 Test Questions 1. A 70 year old male previously received the pneumococcal vaccination (PPSV23) when he was diagnosed with type 2 diabetes at age 50. According to the 2015 American Diabetes Association Standards of Medical Care, the following vaccine is now routinely recommended for him if he has not previously received it: a. Hepatitis B vaccination b. PCV13 vaccination c. Meningococcal vaccination d. Hepatitis A vaccination 2. A 78 year old male with a 20 year history of type 2 diabetes is taking metformin, sitagliptin, glipizide and insulin glargine. His medical problems include hypertension, dyslipidemia, background retinopathy, and a history of a myocardial infarction (10 years ago). His glipizide dose was recently reduced due to mild hypoglycemic episodes. What would be a reasonable A1C target for him according to the American Diabetes Association Guidelines? a. <6% b. <7% c. <8% d. <10% 3. A 52 year old female with type 2 diabetes is taking metformin and glimepiride. She is obese (BMI is 35). Her A1C is 8%. What class of agents would be a reasonable addition to help improve her glycemic control and lose weight? a. GLP-1 receptor agonist b. Thiazolidinedione c. Long-acting insulin d. DPP-4 inhibitor
58 Questions?
59 Thank you for attending! Please write down your CE secret code. All ACPE credit must be claimed online no later than November 20, See Seminar Program Book for details.
Management of Diabetes: A Primary Care Perspective. Presentation Outline
Management of Diabetes: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Presentation Outline
More informationPharmaceutical Management of Diabetes Mellitus
1 Pharmaceutical Management of Diabetes Mellitus Diabetes Mellitus (cont d) Signs and symptoms 2 Elevated fasting blood glucose (higher than 126 mg/dl) or a hemoglobin A1C (A1C) level greater than or equal
More informationClinical Assistant Professor. Clinical Pharmacy Specialist Wesley Family Medicine Residency Program. Objectives
What s New in Diabetes Medications? Matthew Kostoff, PharmD, BCPS, BCACP Clinical Assistant Professor Clinical Pharmacy Specialist Wesley Family Medicine Residency Program Objectives Discuss new literature
More informationNew Treatments for Type 2 Diabetes
New Treatments for Type 2 Diabetes Dr David Hopkins Clinical Director, Division of Ambulatory Care King s College Hospital NHS Foundation Trust Treatments for type 2 diabetes - old & new insulin sulphonylureas
More informationUpdate on the management of Type 2 Diabetes
Update on the management of Type 2 Diabetes Mona Nasrallah M.D Assistant Professor, Endocrinology American University of Beirut 10 th Annual Family Medicine Conference October 14,2011 Global Prevalence
More informationINSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT?
INSULIN AND INCRETIN THERAPIES: WHAT COMBINATIONS ARE RIGHT FOR YOUR PATIENT? MARTHA M. BRINSKO, MSN, ANP-BC CHARLOTTE COMMUNITY HEALTH CLINIC CHARLOTTE, NC Diagnosed and undiagnosed diabetes in the United
More informationDiabetes Mellitus. Melissa Meredith M.D. Diabetes Mellitus
Melissa Meredith M.D. Diabetes mellitus is a group of metabolic diseases characterized by high blood glucose resulting from defects in insulin secretion, insulin action, or both Diabetes is a chronic,
More informationSecond- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief
Second- and Third-Line Approaches for Type 2 Diabetes Workgroup: Topic Brief March 7, 2016 Session Objective: The objective of this workshop is to assess the value of undertaking comparative effectiveness
More informationHarmony Clinical Trial Medical Media Factsheet
Overview Harmony is the global Phase III clinical trial program for Tanzeum (albiglutide), a product developed by GSK for the treatment of type 2 diabetes. The comprehensive program comprised eight individual
More informationtrends in the treatment of Diabetes type 2 - New classes of antidiabetic drugs. IAIM, 2015; 2(4): 223-
Review Article Pharmacological trends in the treatment of Diabetes type 2 - New classes of antidiabetic Silvia Mihailova 1*, Antoaneta Tsvetkova 1, Anna Todorova 2 1 Assistant Pharmacist, Education and
More informationType 2 Diabetes. Aims and Objectives. What did you consider? Case Study One: Miss S. Which to choose?!?! Modes of Action
Aims and Objectives This session will outline the increasing complexities of diabetes care, and the factors that differentiate the combinations of therapy, allowing individualisation of diabetes treatment.
More informationDavid Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010
David Shu, MD, FRCPC Endocrinology, Royal Columbian Hospital October 8 th, 2010 Objectives At the end of the talk, the participants will be able to: 1. Identify the increasing prevalence of type 2 diabetes
More informationHow To Treat Diabetes
Overview of Diabetes Medications Marie Frazzitta DNP, FNP c, CDE, MBA Senior Director of Disease Management North Shore LIJ Health Systems Normal Glucose Metabolism Insulin is produced by beta cells in
More informationCASE A1 Hypoglycemia in an Elderly T2DM Patient with Heart Failure
Hypoglycemia in an Elderly T2DM Patient with Heart Failure 1 I would like to introduce you to Sophie, an elderly patient with long-standing type 2 diabetes, who has a history of heart failure, a common
More informationTargeting the Kidney. Renal Glucose Transport 11/4/2015. Non insulin Agents Available IBITORS. Chao EC, et al. Nat Rev Drug Discovery. 2010;9:551 559.
SGLT-2i and DPP-IVi in the Management of Diabetes Mellitus Type 2 Abel Alfonso, D.O., F.A.C.E. Endocrinologist November 5, 2015 DIABETES: CURRENT RATES AND PROJECTIONS CDC Press Release 2010: 1 in 3 adults
More informationDr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy
Dr. John Bucheit, Pharm.D., BCACP, CDE Clinical Assistant Professor Mercer University College of Pharmacy Disclosures to Participants Requirements for Successful Completion: For successful completion,
More informationNew and Future Treatments for Diabetes. Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014
New and Future Treatments for Diabetes Mary Charlton Specialty Doctor in Diabetes University Hospital Birmingham BARS Oct 2014 Conflicts of interest Investigator Carmelina study of Linagliptin (Boehringer
More informationHow To Get Better Health Care
Kardiovaskulär säkerhet vid behandling av typ 2-diabetes Vad säger senaste data? Michael Alvarsson Kliniken för Endokrinologi, Metabolism och Diabetes Karolinska Universitetssjukhuset Solna Near-normal
More informationCASE B1. Newly Diagnosed T2DM in Patient with Prior MI
Newly Diagnosed T2DM in Patient with Prior MI 1 Our case involves a gentleman with acute myocardial infarction who is newly discovered to have type 2 diabetes. 2 One question is whether anti-hyperglycemic
More informationWhich drugs should be used to treat diabetes in cirrhotic patients?
Which drugs should be used to treat diabetes in cirrhotic patients? Frankfurt am Main 10-12 September 2015 Jörg Bojunga Medizinische Klinik I Johann Wolfgang Goethe-Universität Frankfurt am Main Significance
More informationComparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians
Clinician Research Summary Diabetes Type 2 Diabetes Comparing Medications for Adults With Type 2 Diabetes Focus of Research for Clinicians A systematic review of 166 clinical studies published between
More informationCardiovascular Disease in Diabetes
Cardiovascular Disease in Diabetes Where Do We Stand in 2012? David M. Kendall, MD Distinguished Medical Fellow Lilly Diabetes Associate Professor of Medicine University of MInnesota Disclosure - Duality
More informationVolume 01, No. 08 November 2013
State of New Jersey Department of Human Services Division of Medical Assistance & Health Services New Jersey Drug Utilization Review Board Volume 01, No. 08 November 2013 TO: SUBJECT: PURPOSE: Physicians,
More informationType 2 Diabetes Update For 2015
Type 2 Diabetes Update For 2015 Jerry Meece, RPh, CDE, FACA, FAADE Plaza Pharmacy and Wellness Center jmeece12@cooke.net Learning Objectives At the conclusion of this presentation, the participant will
More informationType 2 Diabetes Medicines: What You Need to Know
Type 2 Diabetes Medicines: What You Need to Know Managing diabetes is complex because many hormones and body processes are at work controlling blood sugar (glucose). Medicines for diabetes include oral
More informationManagement of Type 2 Diabetes Mellitus in the Elderly
Management of Type 2 Diabetes Mellitus in the Elderly ANDREA FERENCZI, M.D. BANNER ARIZONA MEDICAL CLINIC DEPARTMENT OF ENDOCRINOLOGY Incidence and Prevalence of Diabetes in the United States County-level
More information嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 (SGLT2) Inhibitors in Adults with Type 2 Diabetes Mellitus 嘉 義 長 庚 醫 院 藥 劑 科 Speaker : 翁 玟 雯 Diabetes Mellitus : A group of diseases characterized
More informationInsulin or GLP1 How to make this choice in Practice. Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust
Insulin or GLP1 How to make this choice in Practice Tara Kadis Lead Nurse - Diabetes & Endocrinology Mid Yorkshire Hospitals NHS Trust Workshop Over View Considerations/barriers to treatments in type 2
More informationAdd: 2 nd generation sulfonylurea or glinide or Add DPP-4 inhibitor Start or intensify insulin therapy if HbA1c goals not achieved with the above
Guidelines for Type Diabetes - Diagnosis Fasting Plasma Glucose (confirm results if borderline) HbAIC Normal FPG < 00 < 5.5 Impaired Fasting Glucose (IFG) 00 to < 5.7%-.5% Diabetes Mellitus (or random
More informationPrimary Care Type 2 Diabetes Update
Primary Care Type 2 Diabetes Update May 16, 2014 Presented by: Barb Risnes APRN, BC-ADM, CDE Objectives: Discuss strategies to address common type 2 diabetes patient management challenges Review new pharmacological
More informationINSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT
INSULIN TREATMENT FOR TYPE 2 DIABETES MANAGEMENT APIRADEE SRIWIJITKAMOL DIVISION OF ENDOCRINOLOGY AND METABOLISM DEPARTMENT OF MEDICINE FACULTY OF MEDICINE SIRIRAJ HOSPITOL QUESTION 1 1. ท านเคยเป นแพทย
More informationDIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS
Section Two DIABETES MEDICATION-ORAL AGENTS AND OTHER HYPOGLYCEMIC AGENTS This section will: Describe oral agents (pills) are specific for treating type 2 diabetes. Describe other hypoglycemic agents used
More informationTreatment Approaches to Diabetes
Treatment Approaches to Diabetes Dr. Sarah Swofford, MD, MSPH & Marilee Bomar, GCNS, CDE Quick Overview Lifestyle Oral meds Injectables not insulin Insulin Summary 1 Lifestyle & DM Getting to the point
More informationGuidelines for Type 2 Diabetes Diagnosis
Guidelines for Type 2 Diabetes Diagnosis Fasting Plasma Glucose (in asymptomatic individuals, repeat measurement to confirm the test) Normal FPG < 100 2-hr OGTT < 140 HbA1C < 5.5% Impaired Fasting Glucose
More informationCara Liday, PharmD, CDE Associate Professor, Idaho State University Clinical Pharmacist and CDE, InterMountain Medical Center Pocatello, ID The planners and presenter have disclosed no conflict of interest,
More informationAcarbose INITIAL: 25 mg PO TID ($45) Miglitol INITIAL: 25 mg PO TID ($145)
PL Detail-Document #310601 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER June 2015 Drugs for Type 2
More informationManagement of Diabetes in the Elderly. Sylvia Shamanna Internal Medicine (R1)
Management of Diabetes in the Elderly Sylvia Shamanna Internal Medicine (R1) Case 74 year old female with frontal temporal lobe dementia admitted for prolonged delirium and frequent falls (usually in the
More informationDIABETES EDUCATION. *Read package insert each time you refill your medications in case there is new information SULFONYLUREAS
DIABETES EDUCATION *Read package insert each time you refill your medications in case there is new information SULFONYLUREAS ACTION: Sulfonylureas stimulate the pancreas to make more insulin (pancreas
More informationTreatment of Type 2 Diabetes
Improving Patient Care through Evidence Treatment of Type 2 Diabetes This information is based on a comprehensive review of the evidence for best practices in the treatment of type 2 diabetes and is sponsored
More informationDiabetes DIABETES MELLITUS. Types of Diabetes. Classification of Diabetes 6. 10. 2013. Prediabetes: IFG, IGT, Increased A1C
Diabetes Diabetes mellitus is a chronic disease characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. A state of raised blood glucose (hyperglycaemia)
More information10/30/2012. Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University of South Alabama Mobile, Alabama
Faculty Medications for Diabetes Satellite Conference and Live Webcast Wednesday, November 7, 2012 2:00 4:00 p.m. Central Time Anita King, DNP, RN, FNP, CDE, FAADE Clinical Associate Professor University
More informationMedicines for Type 2 Diabetes A Review of the Research for Adults
Medicines for Type 2 Diabetes A Review of the Research for Adults Is This Information Right for Me? Yes, if: Your doctor or health care provider has told you that you have type 2 diabetes and have high
More information25 mg QD-TID @ meals w/1st bite of. food, titrate Q 4 8 weeks; adjust based on 1 postprandial glucose; 100 mg TID max
Table Selected Non-Insulin Antihyperglycemic Agents Class Drug (Brand) Dosing Comments -Glucosidase inhibitors Acarbose a (Precose) 25 mg QD-TID @ meals w/1st bite of MOA: Enzyme inhibitor, delays hydrolysis
More informationDiabetes Mellitus 1. Chapter 43. Diabetes Mellitus, Self-Assessment Questions
Diabetes Mellitus 1 Chapter 43. Diabetes Mellitus, Self-Assessment Questions 1. A 46-year-old man presents for his annual physical. He states that he has been going to the bathroom more frequently than
More informationPharmacological Glycaemic Control in Type 2 Diabetes
Pharmacological Glycaemic Control in Type 2 Diabetes Aim(s) and Objective(s) This guideline aims to offer advice on the pharmacological management for those who require measures beyond diet and exercise
More informationDistinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationGlucose Tolerance Categories. Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies)
Distinguishing between Diabetes Mellitus Type 1 and Type 2, (with Overview of Treatment Strategies) Leann Olansky, MD, FACP, FACE Cleveland Clinic Endocrinology Glucose Tolerance Categories FPG Diabetes
More informationManaging diabetes in the post-guideline world. Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ)
Managing diabetes in the post-guideline world Dr Helen Snell Nurse Practitioner PhD, FCNA(NZ) Overview Pathogenesis of T2DM Aims of treatment The place of glycaemic control Strategies to improve glycaemic
More informationSHORT CLINICAL GUIDELINE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SHORT CLINICAL GUIDELINE SCOPE 1 Guideline title Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes 1.1 Short title Type 2
More informationNew Non-Insulin Therapies for Type 2 Diabetes Mellitus
New Non-Insulin Therapies for Type 2 Diabetes Mellitus Ally P.H. Prebtani Associate Professor of Medicine Internal Medicine, Endocrinology & Metabolism McMaster University Canada Disclosure Relationships
More informationTHE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD
THE PATHOPHYSIOLOGIC BASIS FOR DIABETES TREATMENT: EVALUATING THE EFFECT OF INCRETIN-BASED THERAPIES * Jack Leahy, MD ABSTRACT Type 2 diabetes is a persistent public health challenge that requires innovative
More informationDiabetes Medications. Minal Patel, PharmD, BCPS
Diabetes Medications Minal Patel, PharmD, BCPS Objectives Examine advantages and disadvantages of oral anti-hyperglycemic medications Describe the differences between different classes of insulin Explore
More informationNew and Emerging Diabetes Medications. What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE
New and Emerging Diabetes Medications What do Advanced Practice Nurses Need to Know? Lorraine Nowakowski-Grier,MSN,APRN,BC,CDE Objectives 1) Describe the clinical indications on select emerging novel diabetes
More informationMary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes
Mary Bruskewitz APN, MS, RN, BC-ADM Clinical Nurse Specialist Diabetes Objectives Pathophysiology of Diabetes Acute & Chronic Complications Managing acute emergencies Case examples 11/24/2014 UWHealth
More informationClinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus
World Applied Sciences Journal 7 (1): 01-06, 2009 ISSN 1818-4952 IDOSI Publications, 2009 REVIEW ARTICLE Clinical Efficacy of Gliptins for Glycemic Control in Type 2 Diabeties Mellitus 1 2 3 1 2 Atif Sitwat
More informationAntidiabetic Drugs. Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Antidiabetic Drugs Mosby items and derived items 2011, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Diabetes Mellitus Two types Type 1 Type 2 Type 1 Diabetes Mellitus Lack of insulin production
More informationTake a moment Confer with your neighbour And try to solve the following word picture puzzle slides.
Take a moment Confer with your neighbour And try to solve the following word picture puzzle slides. Example: = Head Over Heels Take a moment Confer with your neighbour And try to solve the following word
More informationEffective Treatment of Type 2 Diabetes
Faculty Disclosures Effective Treatment of Type 2 Diabetes Mellitus Dr. Milligan disclosed no relevant financial relationships with any commercial interests. Steven Milligan, MD Diplomat, American Board
More information6/22/2015. New medicines for type 2 diabetes when do you use them
New medicines for type 2 diabetes when do you use them 1. Oral Secretagogues (e.g. sulfonylureas) 2. Metformin 3. Alpha glucosidase inhibitors 4. Thiazolidinediones 5. GLP-1 receptor agonists 6. DPP-4
More informationUp to Date for Diabetes: Veronica Piziak MD, PhD Professor of Medicine Texas A&M Emeritus Director of Endocrinology Baylor Scott and White
Up to Date for Diabetes: Veronica Piziak MD, PhD Professor of Medicine Texas A&M Emeritus Director of Endocrinology Baylor Scott and White Objectives: What is New in Therapy How to select medications Disclosures:
More informationStatins and Risk for Diabetes Mellitus. Background
Statins and Risk for Diabetes Mellitus Kevin C. Maki, PhD, FNLA Midwest Center for Metabolic & Cardiovascular Research and DePaul University, Chicago, IL 1 Background In 2012 the US Food and Drug Administration
More informationINSULIN INTENSIFICATION: Taking Care to the Next Level
INSULIN INTENSIFICATION: Taking Care to the Next Level By J. Robin Conway M.D., Diabetes Clinic, Smiths Falls, ON www.diabetesclinic.ca Type 2 Diabetes is an increasing problem in our society, due largely
More informationType 2 Diabetes in Children
Type 2 Diabetes in Children February 19, 2005 Brandon Nathan, MD Endocrinology Department of Pediatrics University of Minnesota Medical School University of Minnesota Masonic Children s Hospital Agenda
More informationNew Pharmacotherapies for Type 2 Diabetes
New Pharmacotherapies for Type 2 Diabetes By Brian Irons, Pharm.D., FCCP, BCACP, BCPS, BC-ADM Reviewed by Charmaine Rochester, Pharm.D., BCPS, CDE; and Karen Whalen, Pharm.D., BCPS, CDE Learning Objectives
More informationTYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY. Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU
TYPE 2 DIABETES IN CHILDREN DIAGNOSIS AND THERAPY Ines Guttmann- Bauman MD Clinical Associate Professor, Division of Pediatric Endocrinology, OHSU Objectives: 1. To discuss epidemiology and presentation
More informationDM Management in Elderly- What are the glucose targets?
DM Management in Elderly- What are the glucose targets? AFSHAN ZAHEDI, BASC, MD, FRCP(C) ENDOCRINOLOGY WOMEN S COLLEGE HOSPITAL ASSISTANT PROFESSOR OF MEDICINE UNIVERSITY OF TORONTO NOVEMBER 2, 2011 Disclosures
More informationCardiovascular Effects of Drugs to Treat Diabetes
Cardiovascular Effects of Drugs to Treat Diabetes Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical companies Clinical Trials:
More informationInsulin myths and facts
london medicines evaluation network Insulin myths and facts Statement 1 Insulin is the last resort for patients with Type 2 diabetes After initial metformin and sulfonylurea therapy, NICE and SIGN suggest
More information4/23/2015. Conflict of Interest Disclosure
Endocrine/Diabetes Pharmacology Review May 8, 2015 Chris Winslow, PharmD, MBA and Amanda Brown, PharmD Conflict of Interest Disclosure A conflict of interest exists when an individual is in a position
More informationWhen and how to start insulin: strategies for success in type 2 diabetes
1 When and how to start insulin: strategies for success in type diabetes Treatment of type diabetes in 199: with each step treatment gets more complex Bruce H.R. Wolffenbuttel, MD PhD Professor of Endocrinology
More informationHypoglycemics, Metformins Therapeutic Class Review (TCR)
Hypoglycemics, Metformins Therapeutic Class Review (TCR) December 19, 2013 The literature review is current through February 22, 2016. No part of this publication may be reproduced or transmitted in any
More informationStrengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours
Strengthening the Pharmacist Skills in Managing Diabetes Practice Based Program 27 Contact Hours Presented by New York State Council of Health system Pharmacists October 18 19, 2013 St. John s University,
More informationNoninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause hypoglycemia MED GROUP DESCRIPTOR
Noninsulin Diabetes Medications Summary Chart Medications marked with an asterisk (*) can cause MED GROUP DESCRIPTOR INSULIN SECRETAGOGUES Sulfonylureas* GLYBURIDE* (Diabeta) (Micronase) MICRONIZED GLYBURIDE*
More informationDiabetes Mellitus Pharmacology Review
Diabetes Mellitus Pharmacology Review Hien T. Nguyen, Pharm.D., BCPS Clinical Pharmacist Specialist AtlantiCare Regional Medical Center E-Mail: HienT.Nguyen@atlanticare.org Objectives 1. Review the epidemiology
More informationDiabetes Complications
Managing Diabetes: It s s Not Easy But It s s Worth It Presenter Disclosures W. Lee Ball, Jr., OD, FAAO (1) The following personal financial relationships with commercial interests relevant to this presentation
More informationLong term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE
Long term Weight Management in Obese Diabetic Patients Osama Hamdy, MD, PhD, FACE Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management, Joslin Diabetes Center Assistant
More informationThe basal plus strategy. Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE
The basal plus strategy Denis Raccah, MD, PhD Professor of Medicine University Hospital Sainte Marguerite Marseille FRANCE ADA/EASD guidelines recommend use of basal insulin as early as the second step
More informationUnderstanding diabetes Do the recent trials help?
Understanding diabetes Do the recent trials help? Dr Geoffrey Robb Consultant Physician and Diabetologist CMO RGA UK Services and Partnership Assurance AMUS 25 th March 2010 The security of experience.
More informationAnti-Diabetic Agents. Chapter. Charles Ruchalski, PharmD, BCPS. Drug Class: Biguanides. Introduction. Metformin
Chapter Anti-Diabetic Agents 2 Charles Ruchalski, PharmD, BCPS Drug Class: Biguanides The biguanide metformin is the drug of choice as initial therapy for a newly diagnosed patient with type 2 diabetes
More informationManaging Patients Newly Diagnosed with Diabetes. Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON
Managing Patients Newly Diagnosed with Diabetes Sud Dharmalingam MD, FRCPC Staff Endocrinologist William Osler Health System Brampton, ON 1 Conflict Disclosure Information Conflict Disclosure Information
More informationSubcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes
Subcutaneous Infusion of GLP-1 for 7 Days Improves Glycemic Control Over a Broad Dose Range in Patients with Type 2 Diabetes Mario R. Ehlers, 1,2 Roderick E. Harley, 1 Annette L. Mathisen, 1 Roberta Schneider,
More informationDiabetes Medications: Insulin Therapy
Diabetes Medications: Insulin Therapy Courtesy Univ Texas San Antonio Eric L. Johnson, M.D. Department of Family and Community Medicine Diabetes and Insulin Type 1 Diabetes Autoimmune destruction of beta
More informationMedicines Used to Treat Type 2 Diabetes
Goodman Diabetes Service Medicines Used to Treat Type 2 Diabetes People who have type 2 diabetes may need to take medicine to help lower their blood glucose, in addition to being active & choosing healthy
More informationComparative Review of Oral Hypoglycemic Agents in Adults
SECTION 18.5 Comparative Review of Oral Hypoglycemic Agents in Adults Harinder Chahal For WHO Secretariat Table of Contents Acronyms:... 3 I. Background and Rationale for the review:... 4 II. Medications
More informationType 2 Diabetes - Pros and Cons of Insulin Administration
Do we need alternative routes of insulin administration (inhaled insulin) in Type 2 diabetes? Cons: Suad Efendic Karolinska Institutet, Sweden The Diabetes Management Situation Today Diabetes is a growing
More informationType 2 diabetes is a progressive. status
Type 2 diabetes is a progressive disease: its treatment the current status Associate Professor Jonathan Shaw Why is type 2 diabetes so hard to treat? How to choose the right glucose-lowering g drug? Page
More informationOutline: International Diabetes Federation 2013 11/13/2014. Top 10 countries for prevalence (%) of diabetes (20-79 years) - 2013
ZN, 14AY (11/11/2014) 2 Outline: AMERICAN DIABETES ASSOCIATION UPDATES IN STANDARDS OF MEDICAL CARE IN DIABETES - 2014 Dr. Ziad Nasr, BSc Pharm., Pharm.D. Define current criteria for the diagnosis of diabetes
More informationConsensus Statement for the Management of Type 2 Diabetes
William T. Cefalu, M.D. Profess of Diabetes Associate Executive Direct of Scientific Affairs Chief Scientific Officer Pennington Biomedical Research Center Consensus Statement f the Management of Type
More informationDipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus
REVIEW ARTICLE JIACM 2009; 10(3): 128-33 Dipeptidyl Peptidase-IV Inhibitors: A New Drug in the Therapeutic Armamentarium for Treatment of Type 2 Diabetes Mellitus Rajesh Rajput* Introduction The incidence
More informationType 2 Diabetes Prevention and Therapy. Veronica Piziak MD, PhD Scott and White
Type 2 Diabetes Prevention and Therapy Veronica Piziak MD, PhD Scott and White Disclosures: Research support: J&J Objectives: Epidemiology of diabetes Diagnosis of diabetes Treatment goals Every Day in
More informationwe have to keep up. Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Entity Activity Financial Consideration Comments
Timothy S. Reid, M.D. Mercy Diabetes Center Janesville, WI Entity Activity Financial Consideration Comments Novo Nordisk Speaker/Consultant Speaker Fees/Honoraria Sanofi-Aventis Speaker/Consultant Speaker
More informationEFFIMET 1000 XR Metformin Hydrochloride extended release tablet
BRAND NAME: Effimet XR. THERAPEUTIC CATEGORY: Anti-Diabetic PHARMACOLOGIC CLASS: Biguanides EFFIMET 1000 XR Metformin Hydrochloride extended release tablet COMPOSITION AND PRESENTATION Composition Each
More informationDrug Class Review. Newer Diabetes Medications and Combinations
Drug Class Review Newer Diabetes Medications and Combinations Final Streamlined Update 1 Report June 2014 The purpose of Drug Effectiveness Review Project reports is to make available information regarding
More informationAntihyperglycemic Agents Comparison Chart
Parameter Metformin Sulfonylureas Meglitinides Glitazones (TZD s) Mechanism of Action Efficacy (A1c Reduction) Hepatic glucose output Peripheral glucose uptake by enhancing insulin action insulin secretion
More informationIntensifying Insulin Therapy
Intensifying Insulin Therapy Rick Hess, PharmD, CDE, BC-ADM Associate Professor Gatton College of Pharmacy, Department of Pharmacy Practice East Tennessee State University Johnson City, Tennessee Learning
More informationInsulin and Other Glucose-Lowering Drugs
Insulin and Other Glucose-Lowering Drugs I. OVERVIEW The pancreas is both an endocrine gland that produces the peptide hormones insulin, glucagon, and somatostatin and an exocrine gland that produces digestive
More informationAntihyperglycemic Agents in the Treatment of Patients with Type 2 Diabetes
Antihyperglycemic Agents in the Treatment of Patients with Type 2 Diabetes Financial Disclosures Janssen Research & Development, LLC- Research Grant Unlabeled/Unapproved Uses Disclosure-None Learning Objectives
More informationBritni Hebert, MD PGY-1
Britni Hebert, MD PGY-1 Importance of Diabetes treatment Types of treatment Comparison of treatment/article Review Summary Example cases 1 out of 13 Americans have diabetes Complications include blindness,
More informationDiabetes: When To Treat With Insulin and Treatment Goals
Diabetes: When To Treat With Insulin and Treatment Goals Lanita. S. White, Pharm.D. Director, UAMS 12 th Street Health and Wellness Center Assistant Professor of Pharmacy Practice, UAMS College of Pharmacy
More informationTherapeutic Choices within Diabetes. Abeer Alsaweer, MBBS, CABFM*
Bahrain Medical Bulletin, Vol. 35, No. 2, June 2013 Education-Family Physician Corner Therapeutic Choices within Diabetes Abeer Alsaweer, MBBS, CABFM* The field of diabetes has experienced various evolutionary
More information